82 related articles for article (PubMed ID: 18262771)
21. Pilot and Feasibility Studies of a Lifestyle Modification Program Based on the Health Belief Model to Prevent the Lifestyle-Related Diseases in Patients with Mental Illness.
Tsubata N; Kuroki A; Tsujimura H; Takamasu M; IIjima N; Okamoto T
Healthcare (Basel); 2023 Jun; 11(12):. PubMed ID: 37372808
[TBL] [Abstract][Full Text] [Related]
22. Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.
Correll CU; Højlund M; Graham C; Todtenkopf MS; McDonnell D; Simmons A
Int J Neuropsychopharmacol; 2023 Jul; 26(7):451-464. PubMed ID: 37326421
[TBL] [Abstract][Full Text] [Related]
23. Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study.
Rikhari P; Kumar A; Agrawal P; Kumar H
J Family Med Prim Care; 2022 May; 11(5):2194-2200. PubMed ID: 35800481
[TBL] [Abstract][Full Text] [Related]
24. Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort.
Xing M; Sheng J; Cui M; Su Y; Zhang C; Chen X; Fang Y; Cui D; Li Z
Curr Neuropharmacol; 2022; 20(10):1969-1977. PubMed ID: 35236263
[TBL] [Abstract][Full Text] [Related]
25. Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis.
Li R; Zhang Y; Zhu W; Ding C; Dai W; Su X; Dai W; Xiao J; Xing Z; Huang X
Sci Rep; 2020 Oct; 10(1):17028. PubMed ID: 33046806
[TBL] [Abstract][Full Text] [Related]
26. Considering the Microbiome in Stress-Related and Neurodevelopmental Trajectories to Schizophrenia.
Hoffman KW; Lee JJ; Corcoran CM; Kimhy D; Kranz TM; Malaspina D
Front Psychiatry; 2020; 11():629. PubMed ID: 32719625
[TBL] [Abstract][Full Text] [Related]
27. THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE.
Dehelean L; Romosan AM; Manea MM; Papava I; Andor M; Romosan RS
Acta Endocrinol (Buchar); 2019; 15(3):342-348. PubMed ID: 32010353
[TBL] [Abstract][Full Text] [Related]
28. Drug-naive patients with schizophrenia have metabolic disorders that are not associated with polymorphisms in the LEP (-2548G/A) and 5-HTR2C (-759C/T) genes.
Chen J; Tan L; Long Z; Wang L; Hu L; Yang D
Int J Clin Exp Pathol; 2018; 11(12):5969-5980. PubMed ID: 31949685
[TBL] [Abstract][Full Text] [Related]
29. Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana.
Owusu-Ansah A; Berko Panyin A; Obirikorang C; Agyare C; Acheampong E; Kwofie S; Odame Anto E; Nsenbah Batu E
Schizophr Res Treatment; 2018; 2018():6542983. PubMed ID: 30050695
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics.
Jeong SH; Lee NY; Kim SH; Chung IW; Youn T; Kang UG; Ahn YM; You HY; Kim YS
Psychiatry Investig; 2018 Jun; 15(6):628-637. PubMed ID: 29940717
[TBL] [Abstract][Full Text] [Related]
31. Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications.
Bozymski KM; Whitten JA; Blair ME; Overley AM; Ott CA
Community Ment Health J; 2018 Aug; 54(6):717-724. PubMed ID: 29127566
[TBL] [Abstract][Full Text] [Related]
32. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.
Pillinger T; Beck K; Stubbs B; Howes OD
Br J Psychiatry; 2017 Dec; 211(6):339-349. PubMed ID: 28982658
[No Abstract] [Full Text] [Related]
33. Metabolic syndrome in antipsychotic naive African patients with severe mental illness in usual care.
Saloojee S; Burns JK; Motala AA
Early Interv Psychiatry; 2018 Dec; 12(6):1137-1143. PubMed ID: 28402033
[TBL] [Abstract][Full Text] [Related]
34. Exercise as an intervention for first-episode psychosis: a feasibility study.
Firth J; Carney R; Elliott R; French P; Parker S; McIntyre R; McPhee JS; Yung AR
Early Interv Psychiatry; 2018 Jun; 12(3):307-315. PubMed ID: 26987871
[TBL] [Abstract][Full Text] [Related]
35. Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.
Medici V; McClave SA; Miller KR
Curr Gastroenterol Rep; 2016 Jan; 18(1):2. PubMed ID: 26700070
[TBL] [Abstract][Full Text] [Related]
36. Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit.
Grover S; Nebhinani N; Chakrabarti S; Avasthi A; Basu D; Kulhara P; Mattoo SK; Malhotra S
Indian J Psychiatry; 2014 Oct; 56(4):371-6. PubMed ID: 25568478
[TBL] [Abstract][Full Text] [Related]
37. Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.
Riordan HJ; Antonini P; Murphy MF
Am Health Drug Benefits; 2011 Sep; 4(5):292-302. PubMed ID: 25126357
[TBL] [Abstract][Full Text] [Related]
38. Metformin and berberine prevent olanzapine-induced weight gain in rats.
Hu Y; Young AJ; Ehli EA; Nowotny D; Davies PS; Droke EA; Soundy TJ; Davies GE
PLoS One; 2014; 9(3):e93310. PubMed ID: 24667776
[TBL] [Abstract][Full Text] [Related]
39. Metabolic syndrome in schizophrenia.
Malhotra N; Grover S; Chakrabarti S; Kulhara P
Indian J Psychol Med; 2013 Jul; 35(3):227-40. PubMed ID: 24249923
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.
Vancampfort D; Wampers M; Mitchell AJ; Correll CU; De Herdt A; Probst M; De Hert M
World Psychiatry; 2013 Oct; 12(3):240-50. PubMed ID: 24096790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
